The review highlights recently discovered mechanisms that sustain castration-resistant prostate cancer (CRPC) growth and describes advances in CRPC therapeutics.
INTRODUCTION
Prostate cancer is the second leading cause of cancer death in American men and mortality remains high despite improvements in therapy [1] . Whereas the majority of primary prostate tumors are treated successfully by radical prostatectomy or external beam radiotherapy, some tumors progress to invasive and disseminated disease. Patients with metastatic prostate cancer are treated with androgen deprivation therapy (ADT) through either chemical or surgical castration. Initial responses to ADT approach 100%, but complete remissions are rare and progressive cancer growth generally resumes after a median of 2-3 years [2] . The emergent castration-resistant prostate cancer (CRPC) is generally incurable with existing treatment approaches.
Because ADT is initially effective and there is copious evidence supporting the re-expression of androgen-regulated signaling in CRPC, most investigational therapies have focused on developing a more potent blockade of androgen receptor (AR) transcriptional activity and the synthesis of androgenic ligands [2] . In this review we report recent advancements in deciphering AR signaling and regulation, identifying mechanisms of intratumoral androgen maintenance, and the development of novel therapies directed toward the AR pathway.
Androgen receptor signaling in castrationresistant prostate cancer AR signaling is critical to the development of the normal prostate and in the progression from primary to metastatic disease. Continued reliance on AR signaling for survival is a hallmark of CRPC, demonstrated by re-expression of androgen-regulated genes (ARGs) after castration [2] and the susceptibility of tumors refractory to conventional ADT to more potent androgen pathway inhibitors [3 && ,4,5 & ]. Therefore, discovering mechanisms of AR expression and AR-driven transcription in tumor cells is imperative.
Regulation of androgen receptor expression
The AR is commonly altered in CRPC with genomic amplification and/or overexpression occurring in up to approximately 60% of CRPC metastasis [6 & ]. In addition to genomic alterations, a recent study identified nongenomic mechanisms leading to AR up-regulation in advanced prostate cancers ( Fig. 1 ). Analysis of androgen-dependent prostate cancer cell lines identified an AR-regulated enhancer element located within the second intron of the AR gene itself. Low AR signaling was shown to activate this enhancer and up-regulated AR expression. Restoration of AR signaling caused AR to bind the enhancer and recruit lysine-specific demethylase 1 (LSD1) which repressed transcription, demonstrating a negative feedback program that limits endogenous AR expression in normal tissues [7 && ]. However, when androgen-dependent prostate cancer cells were grown under castrate levels of androgen, low AR transcriptional activity resulted in up-regulated AR expression, an event that consequently maintains the cellular program of AR-regulated genes. The investigators concluded that the measurable, but low levels of AR ligand in CRPC are sufficient to engage enhancer elements in AR target genes, but insufficient to recruit AR and attendant cofactors to suppressor elements, thus providing a net pro-growth and survival effect without suppressing the AR itself.
The AR was also recently shown to be regulated through novel functions of the well characterized retinoblastoma tumor suppression protein. Two independent studies identified widespread genomic loss of retinoblastoma in primary tumors ($5%) and CRPC (35%) [6 & ], with a loss of retinoblastoma protein in up to 74% of CRPC [8 & ]. Experimentally, loss of normal retinoblastoma function enhanced lymph node carcinoma of the prostate (LNCaP) xenograft growth in castrate mice. Upon further investigation, this survival benefit was not mediated by losing classical retinoblastoma tumor suppressor function, but through an alternate mechanism that involved the consequent up-regulated E2F1 expression. In retinoblastoma-deficient cells E2F1 was shown to be recruited to the AR regulatory locus resulting in increased AR expression and transcriptional activity, and attendant maintenance of the AR transcriptional program [8 & ].
Regulation of androgen receptor transcriptional activity
The action and specificity of nuclear steroid hormone receptors is determined by cofactor binding
KEY POINTS
Androgen receptor (AR) signaling remains the dominant growth pathway in prostate cancers that progress in the setting of low serum androgens.
There is evidence that PI3K/AKT/mTOR signaling can bypass the need for AR in PTEN-null tumors.
Emerging anti-AR and antiandrogen biosynthesis pharmaceuticals are an improvement over conventional ADT, although CRPC recurring from second-line ADT suggests that more aggressive ADT is still necessary. [9]. A recent large-scale genomic analysis of primary and metastatic tumors found a novel AR cofactor, nuclear receptor coactivator 2 (NCOA2), to be upregulated in a subset of primary (8%) and metastatic tumors (37%). Follow-up experiments in LNCaP cells found that NCOA2 expression correlated with an increased AR transcriptional response to dihydrotestosterone (DHT). NCOA2 overexpression in primary tumors also correlated with a higher risk of recurrence, linking AR activity in primary tumors to future adverse outcomes [6 & ]. In addition to globally increased AR activity, altered AR signaling in CRPC appears to alter the spectrum of transcriptional targets. A striking example of an alternative AR transcriptional program emerged from experiments comparing ARGs in the androgen-dependent cell model LNCaP and its castration-resistant (CR) subline LNCaP-abl. Wang et al. [10] discovered that the AR binding sites and resulting transcript profile in LNCaP-abl were enriched for genes promoting M-phase progression, notably ubiquitin-conjugating enzyme E2C (UBE2C). UBE2C expression was also found to be up-regulated in clinical CRPC [10] . Other studies have also identified a shift towards pro-mitotic gene expression in conjunction with decreased AR signaling. However, an alternative hypothesis regarding increased mitosis stems from a decrease in the pro-differentiation role of AR, and not a global change in the repertoire of genes regulated by AR
None-the-less, these findings necessitate a reassessment of the influence of unliganded AR in mediating key drivers of cell growth.
Androgen receptor splice variants
A substantial number of genes encoded by the genome are transcribed with alternative exon usage and the AR is among this group. Of relevance to CRPC, several AR splice variants (ARVs) encoding ligand-binding-domain (LBD) deficient receptors represent a newly discovered mechanism contributing to ADT resistance. ARVs were initially discovered in the CWR22R xenograft line, and have since been ] demonstrated that several ARVs remain dependent on AR FL heterodimerization for nuclear translocation and transcriptional activity, and overall AR activity remains sensitive to LBD-targeted antiandrogens.
Among the recently described ARVs is a transcript that is devoid of exons 5-7 encoding the LBD, designated AR v567es , but retaining the hinge region necessary for nuclear translocation [14] . This ARV is constitutively localized to the nucleus and appears to be less dependent on AR FL for transcriptional activity. AR v567es can up-regulate AR FL expression and induce a subset of ARGs in a ligand-independent fashion, supporting a mechanism for CR growth. LNCaP cells engineered to express AR v567es also up-regulate a cohort of genes not known to be influenced by the ligand-activated full-length receptor, suggesting this AR variant controls a unique transcriptional program [12 && ,15] . To date, two ARVs identified in human cancer (AR-V7, AR v567es ) and one identified in a mouse model (mAR-V4) have been shown to significantly enhance survival in androgen-deprived prostate cell lines and are up-regulated in response to castration [12 && ,13 & ]. Those ARVs dependent on AR FL for transcriptional activity (AR-V7 and mAR-V4) are sensitive to AR FL inhibitors [13 & ]. There are no published data regarding the sensitivity of AR v567es to inhibition by new potent AR antagonists; however, effective blockade seems unlikely since AR v567es translocates to the nucleus and activates ARGs in the absence of AR FL [12 && ]. Thus, since AR v567es is also commonly found in clinical CRPC [12 && ], therapeutics that effectively inhibit AR activity through a non-LBD mechanism may be required to successfully treat prostate cancers that express this AR type.
Maintenance of intratumoral androgens
In men, extra-testicular androgen production occurs in adrenal glands and recent studies suggest that synthesis may also occur de novo in CRPC [16 & -19 & ]. The efficacy of steroid synthesis inhibitors in clinical trials supports the importance of extra-testicular ligand production in clinical disease [20 && ] and there is emerging evidence suggesting that active steroid transport also plays a role in ADT resistance.
Androgen synthesis
Two novel mechanisms of regulating androgen biosynthesis were discovered by studying androgendependent prostate cancer models. In one pathway, Locke et al. [17 & ] investigated androgen-stimulated cholesterol-ester production in prostate cancer. They discovered that cholesterol-esters are broken down into cholesterol and fatty acid in response to ADT. Fatty acid is further converted to arachidonic acid, which initiates a transcription program that increases steroid acute regulatory protein (StAR) expression. StAR co-localizes with CYP11A on the mitochondrial membrane and catalyzes the rate-limiting step in steroid biosynthesis: conversion of cholesterol to pregnenelone. Further investigation demonstrated increased expression of steroidogenic enzymes and de-novo steroid synthesis in androgen-deprived LNCaP cells that were stimulated with exogenous arachidonic acid [17 & ]. Hyperinsulinemia, a clinically observed sideeffect of ADT, can activate an alternative intratumoral steroid biosynthesis pathway. Insulin treatment was sufficient to induce steroid biosynthesis in the three widely used cell line models of androgen-dependent prostate cancer. Following insulin stimulation, intracellular and secreted steroids were present in levels sufficient to induce ARG expression. Importantly, insulin up-regulated the expression of StAR [18 & ], similar to the result of arachidonic acid stimulation [17 & ], revealing a common, and potentially druggable target in intratumoral androgen synthesis.
Androgen transport
Steroid hormones enter cells primarily via passive diffusion through the plasma membrane, but several studies now indicate that active transport by organic anion-transport polypeptides (OATP super-family, encoded by the SLCO gene family) contributes to ADT resistance. OATPs transport many known drugs and small molecules, including steroid hormones [21] . The clinical relevance of these transporters in CRPC is supported by recent studies demonstrating that a subgroup of clinical prostate cancers overexpresses specific members of the SLCO family and outcome analyses of two independent patient cohorts demonstrated that genomic variants of SLCO2B1 and SLCO1B3 associated with a shorter time to disease progression [22 & ] and higher rates of prostate specific mortality [23 & ]. The associations of SLCO2B1 and SLCO1B3 variants with higher mortality are clinically significant because they are both androgen transporters [24, 25] ; however, polymorphisms in each gene are associated with differential rates of steroid transport. Cell-line experiments showed contrasting levels of dihydroepiandosterone (DHEAS) transport between 3 SLCO2B1 SNP variants. SLCO1B3 SNP variants were not associated with shorter patient time to progression in isolation, but interacted with SLCO2B1 variants that confer high-DHEAS transport to decrease patient time to disease progression [22 & ].
Androgen receptor interactions with oncogenic signaling pathways
Inactivation of the phosphatase and tensin homolog (PTEN) tumor suppressor is one of the most common abnormalities found in prostate cancers [6 & ]. PTEN inactivation de-regulates PI3K/AKT signaling and engages multiple survival and proliferation pathways. The interaction between the PI3K/ AKT pathway and AR activity is complex. Whereas early studies suggested that AKT phosphorylation of AR repressed androgen-mediated transcription [26] , other studies suggest that PI3K/ATK activation results in a net increase in proliferation and ARG expression [27 && ]. However, recent publications suggest a more complex feedback loop between PTEN, PI3K/AKT signaling, and AR activity.
Two independent studies using the PTEN conditionally-null mouse model of prostate cancer incorporated PTEN/AKT-mediated AR suppression into a feedback loop. Whereas both studies determined that PTEN deletion reduces AR expression, the mechanisms contributing to these events varied. Carver et al. [28 && ] proposed a model in which AR activity is up-regulated by HER kinase activation which in turn is inhibited by AKT activity. Therefore, PTEN loss and increased AKT signaling inhibit HER kinases and consequently diminish AR activity (Fig. 2) . Thus, pharmacological inhibition of the AKT pathway resulted in the paradoxical re-activation of AR signaling. However, previously published studies on HER kinase activation in human models of prostate cancer reported HER kinase activity decreased AR expression [29] . Reciprocal interactions whereby active AR signaling suppressed AKT signaling via FKBP5 and PHLPP intermediaries provide a rationale for co-targeting these pathways. Though clinical trials of HER inhibitors as monotherapy in CRPC have not yielded substantial responses, serum PSA declines have been noted in some patients [30, 31] . This may be the result of reduced tumor burden or decreased AR activity. Clearly, the effect of HER kinase activity, the PI3K pathway, and relationships with AR signaling in prostate cancer are incompletely understood and further investigation is needed in order to design clinical studies that exploit their interactions.
A second model, proposed by Mulholland et al. [27 && ], suggests that PTEN loss, independent of AKT, represses AR activity. Further, using elegant genetically engineered mouse models that completely ablated AR signaling in prostate cancerssomething not yet achieved in humans -the investigators demonstrated that the resulting AR-null cancers arising in a Pten-null genetic background had substantially increased rates of cell proliferation. While proposing somewhat different mechanisms, the significant contribution of these studies is evidence that AKT activation combined with PTEN loss is sufficient for prostate tumor growth in the absence of robust AR signaling, and may actively repress the AR program. Thus, further reduction in AR activity by more potent ADT might select for tumors with activated PI3K/AKT/mTOR signaling and little or no residual AR activity.
Androgen receptor pathway-directed therapies
Clinically, the emergence of CRPC is reflected by the progressive growth of metastatic tumors in the absence of serum androgens which is accompanied by the reactivation of the AR program as exemplified by rising serum concentrations of PSA. To continue targeting this reactivated AR pathway, new potent pharmacological inhibitors of ligand synthesis and the AR have been developed and shown to be of clinical benefit.
Antiandrogens
Conventional AR antagonists offer incomplete transcriptional inhibition, and exhibit partial agonist activity in the presence of mutated AR, high levels of the AR, or high concentrations of inhibitor. Thus, more potent antagonists lacking agonist activity are necessary. A promising novel antiandrogen, MDV-3100, recently completed a phase I/II trial in 140 patients with CRPC. Of those treated, 56% experienced a more than 50% decrease in serum PSA, and imaging demonstrated that 22% of patients with soft tissue metastasis and 56% of patients with bony metastasis saw a stabilization of disease. Furthermore, there was no evidence of agonist activity and dose-related fatigue was the most common side effect [5 & ]. Formal reports of ongoing phase 3 clinical trials are eagerly awaited.
Most AR antagonist development has targeted the C-terminal LBD, a domain that is lost in ARVs [12 && ,13 & ]. The AR N-terminal domain contains the DNA-binding elements common to both AR FL and ARVs. Thus, inhibition of all AR forms could potentially be accomplished via N-terminal disruption. Andersen et al. [3 && ] recently reported studies of a novel small-molecule N-terminal AR inhibitor, EPI-001. EPI-001 specifically binds the AR Nterminus and disrupts transcription and proteinprotein interactions. Preliminary investigation showed that EPI-001 treatment caused decreased ARG expression and inhibited LNCaP xenograft growth in intact mice. Furthermore, EPI-001 inhibited LBD-deficient ARV activity [3 && ].
While not yet ready for clinical trials, EPI-001 is a significant discovery that will serve as a lead compound to identify other AR N-terminal inhibitors.
Androgen synthesis inhibitors
Recently, a phase III trial was completed that demonstrated improved outcomes in patients treated with abiraterone acetate, an irreversible CYP17A inhibitor. Patients previously treated with docetaxel received a combination of abiraterone/ prednisone or placebo/prednisone. Overall survival was significantly increased in patients treated with abiraterone (14.8 months) versus patients treated with placebo (10.9 months). All other secondary endpoints (PSA response, time to PSA progression, progression-free survival) were also improved in the abiraterone treatment group. Furthermore, the side effect profile was generally limited to the effects of mineralocorticoid excess [20 && ]. Importantly, disease progression on abiraterone was associated with a rising PSA, once again indicating incomplete suppression of AR signaling. Whereas abiraterone-resistant tumors have not yet been evaluated from men who have relapsed on abiraterone treatment, mechanisms of resistance have been investigated in vivo using prostate cancer xenografts. Reminiscent of AR-inhibitor trials in-vivo abiraterone resistance appears to occur via up-regulation of the drug target, CYP17A, along with higher expression of ARV or mutated AR [16 & ,19 & ]. This underscores a continued reliance on AR-mediated transcriptional pathways, suggesting that combination therapy co-targeting the AR and CYP17A might evoke a more prolonged therapeutic response.
CONCLUSION
The heterogeneous molecular composition of advanced CRPC makes treatment very challenging. However, a common feature involves the activation and re-expression of the AR program following ADT. Of relevance for therapeutics, the molecular mechanisms resulting in ARG re-expression appear to be diverse. Current literature suggests that tumors re-express ARGs following ADT by up-regulation of the targeted pathway (e.g. CYP17), activation of an alternative pathway of resistance -of which there appear to be several, or both. It is important that future work focus on the development of additional ligand and synthesis inhibitors, in addition to investigating combination therapy between different ADT modalities (androgen synthesis inhibitors with more potent AR antagonists, for example). Targeting newly implicated ADT resistance mechanismssuch as ARVs, NCOA2, HER kinases, and AKT/ PI3K -in combination with existing therapy may act to further suppress CRPC.
A potential application of recent studies would be to tailor therapy to prostate cancer subtypes. For example, ADT use in primary prostate cancer has produced mixed results and is associated with significant morbidity [32] . Molecular analyses of tumors prior to, or during therapy may assist in rationally selecting patients with specific ARenhancing pathways for co-targeting strategies. Finally, there is emerging experimental and clinical evidence of prostate tumors that can completely overcome their dependence on AR [27 && ,28 && ,33], and it is plausible that aggressive ADT may select for tumors that are truly androgen pathwayindependent. Mechanisms of androgen pathway independence should be investigated in more depth to identify potential therapeutic targets in order to anticipate the emergence of this clinically important variant of prostate cancer.
